Biotechnology & Life Sciences Global On demand · 24-48h

Global Messenger RNA Vaccines and Therapeutics Market Strategic Research Report

Global Messenger RNA Vaccines and Therapeutics Market Strate…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Messenger RNA Vaccines and Therapeutics Market
$14.62B2025
13.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Self-amplifying, Conventional Non-amplifying

By Application: Cancer, Infectious Diseases, Autoimmune Diseases, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: BioNTech, Moderna, CureVac, Pfizer, Glaxo Smith Kline's, Daiichi Sankyo Company, Intellia Therapeutics, Arcturus Therapeutics, Emmy Vaccine, CSPC, CanSino, Fosun Pharma

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 107 pages
Market size 2025
$14.62B
Billion USD
Forecast CAGR
13.1%
2025-2032
Forecast 2032
$34.6B
Projected
영역들
5
Asia Pacific · Latin America · MEA · Europe · North America

개요

Scope of the Report

The global Messenger RNA Vaccines and Therapeutics market size is predicted to grow from US$ 14,620 million in 2025 to US$ 34,010 million in 2032; it is expected to grow at a CAGR of 13.1% from 2026 to 2032.

An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA to generate an immune response. [1] Such vaccines deliver antigen-coding mRNA molecules into immune cells, which use the designed mRNA as a template to build foreign proteins normally produced by pathogens such as viruses or cancer cells. These protein molecules stimulate an adaptive immune response, teaching the body to recognize and destroy the corresponding pathogen or cancer cell. mRNA is composed of RNA encapsulated in lipid nanoparticles, which protect the RNA strand and facilitate its uptake into cells. Reactogenicity, the propensity of the vaccine to produce adverse reactions, was similar to that of traditional non-RNA vaccines. People prone to autoimmune reactions may experience adverse reactions to messenger RNA vaccines. Compared with traditional vaccines, mRNA vaccines have the advantages of being easy to design, fast in production, low in cost, capable of inducing cellular and humoral immunity, and not interacting with genomic DNA.

Global key Messenger RNA Vaccines and Therapeutics players cover BioNTech, Moderna, CureVac, Pfizer, Glaxo Smith Kline's, etc.

This report presents a comprehensive overview of the global Messenger RNA Vaccines and Therapeutics market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Self-amplifying
  • Conventional Non-amplifying

Segment by Application

  • Cancer
  • Infectious Diseases
  • Autoimmune Diseases
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Messenger RNA Vaccines and Therapeutics market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Cancer, Infectious Diseases, Autoimmune Diseases evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Messenger RNA Vaccines and Therapeutics Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 13.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$14.62B
2025
Forecast
$34.6B
2032
CAGR
13.1%
2025–2032
영역들
5
global
Key companies
BioNTechModernaCureVacPfizerGlaxo Smith Kline'sDaiichi Sankyo CompanyIntellia TherapeuticsArcturus Therapeutics
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Self-amplifyingConventional Non-amplifying
By Application
CancerInfectious DiseasesAutoimmune DiseasesOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Self-amplifying
  • 3.1.3 Conventional Non-amplifying
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Cancer
  • 4.1.3 Infectious Diseases
  • 4.1.4 Autoimmune Diseases
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 BioNTech
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Moderna
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 CureVac
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Pfizer
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Glaxo Smith Kline's
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Daiichi Sankyo Company
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Intellia Therapeutics
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Arcturus Therapeutics
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Emmy Vaccine
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 CSPC
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 CanSino
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Fosun Pharma
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Messenger RNA Vaccines and Therapeutics market size?
The global Messenger RNA Vaccines and Therapeutics market is estimated at US$ 14.62 billion in 2025 (base year) and is projected to reach US$ 34.01 billion by 2032.
What growth rate is expected for the Messenger RNA Vaccines and Therapeutics market through 2032?
The market is expected to grow at a CAGR of 13.1% from 2026 to 2032, expanding from US$ 14.62 billion in 2025 to US$ 34.01 billion in 2032, roughly 2.3 times its base-year value.
How is Messenger RNA Vaccines and Therapeutics defined?
An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA to generate an immune response. [1] Such vaccines deliver antigen-coding mRNA molecules into immune cells, which use the designed mRNA as a template to build foreign proteins normally produced by pathogens such as viruses or cancer cells. Reactogenicity, the propensity of the vaccine to produce adverse reactions, was similar to that of traditional non-RNA vaccines.
What are the main segments of the Messenger RNA Vaccines and Therapeutics market by type?
By type, the market is segmented into Self-amplifying and Conventional Non-amplifying.
Which applications drive demand in the Messenger RNA Vaccines and Therapeutics market?
Key applications covered include Cancer, Infectious Diseases, Autoimmune Diseases and Others.
Who are the key players in the Messenger RNA Vaccines and Therapeutics market?
Key players profiled include BioNTech, Moderna, CureVac, Pfizer, Glaxo Smith Kline's, Daiichi Sankyo Company, Intellia Therapeutics and Arcturus Therapeutics, among 12 companies covered in total.
Which regions and countries are covered for Messenger RNA Vaccines and Therapeutics?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Messenger RNA Vaccines and Therapeutics market report?
The report is intended for manufacturers and solution providers, distributors and end users in Cancer, Infectious Diseases and Autoimmune Diseases, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Messenger RNA Vaccines and Therapeutics market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.